Peptidylarginine Deiminases (PADs) catalyze the post-translational conversion of arginine residues to citrulline. PAD4 is localized to the nucleus of neutrophils where it citrullinates the core histones H3, H4 and H2A. PAD4-mediated histone citrullination is required for the generation of Neutrophil Extracellular Traps (NETs), aggregates of DNA and anti-microbial proteins that are expelled from neutrophils to ensnare and kill bacteria. The majority of patients with Rheumatoid Arthritis (RA) produce antibodies to citrullinated proteins, suggesting a role for PAD4 in the pathogenesis of this disease.
PAD4 has also been recognized as a transcriptional coregulator. It is recruited to the promoters of genes regulated by the estrogen receptor (ER) and p53, where it catalyzes the citrullination of the N-terminal portion of histone H3 and inhibits arginine methylation. Recently, it was reported that a member of the ETS oncogene family, Elk-1 is citrullinated by PAD4 to activate c-fos expression in breast cancer cells.
References:
Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR. Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel. 2009 Sep;12(5):616-27. PMID: 19736621; PMCID: PMC3771078.
Rohrbach AS, Slade DJ, Thompson PR, Mowen KA. Activation of PAD4 in NET formation. Front Immunol. 2012;3:360. Published 2012 Nov 29. doi:10.3389/fimmu.2012.00360
Urano T, Nakayama M, Ohara O, Yamamura K, Yamamoto K, Miyazaki T. PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression. Nat Commun. 2013;4:1836. doi: 10.1038/ncomms2862. PMID: 23673621; PMCID: PMC3674250.
Koushik S, Joshi N, Nagaraju S, Mahmood S, Mudeenahally K, Padmavathy R, Jegatheesan SK, Mullangi R, Rajagopal S. PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis. Expert Opin Ther Targets. 2017 Apr;21(4):433-447. doi: 10.1080/14728222.2017.1294160. Epub 2017 Feb 22. PMID: 28281906.
Nakashima K, Arai S, Suzuki A, Nariai Y, Urano T, Nakayama M, Ohara O, Yamamura K, Yamamoto K, Miyazaki T. PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression. Nat Commun. 2013;4:1836. doi: 10.1038/ncomms2862. PMID: 23673621; PMCID: PMC3674250.
Oxford Biomedical Research
OBR公司开发,生产和销售检测试剂盒,重组蛋白和应用于生物医学和制药研究的抗体,现已具有400多种产品。
认识到减少疾病和改善人类健康将需要开发出更好的方法来识别和量化疾病的潜在危险因素,牛津生物医学研究(OBR)致力于为生物医学研究人员提供最佳的工具,用于分析氧化应激慢性炎症-两种最重要的危险因素,在多种人类疾病的发展中发挥关键作用,包括癌症,心血管疾病,糖尿病和神经变性。
产品列表:
没有。 | 品牌 | 货号 | 名称 | 规格 |
1 | 牛津生物医学研究 | IS20 | 1.0毫克 | |
2 | 牛津生物医学研究 | FR18 | 人血浆乳铁蛋白测定试剂盒 | 1套 |
3 | 牛津生物医学研究 | TA02 | 总抗氧化剂电源套件 | 1套 |
4 | 牛津生物医学研究 | PR32 | 抗兔CYP450 2E1 | 0.1毫升 |
5 | 牛津生物医学研究 | CE2B6.250 | 250毫克 | |
6 | 牛津生物医学研究 | GS70 | 0.1毫克 | |
7 | 牛津生物医学研究 | GS22 | 0.005毫克 | |
8 | 牛津生物医学研究 | PH91 | 100微克 | |
9 | 牛津生物医学研究 | PK50 | 面板 | |
10 | 牛津生物医学研究 | NS25 | 0.1毫克 | |
11 | 牛津生物医学研究 | UP33 | 0.05毫克 | |
12 | 牛津生物医学研究 | PK42 | 0.1毫克 | |
13 | 牛津生物医学研究 | PI66 | 1.0毫克 | |
14 | 牛津生物医学研究 | FS35 | 1套 | |
15 | 牛津生物医学研究 | MP12 | 0.001毫克 |